文献速递病毒性肝炎

替诺福韦艾拉酚胺富马酸盐:治疗慢性乙型肝炎的新型替诺福韦前药

Tenofovir Alafenamide Fumarate: A New Tenofovir Prodrug for the Treatment of Chronic Hepatitis B Infection.
PubMed 文献 · J Infect Dis · 2017-01-01

替诺福韦艾拉酚胺富马酸盐(TAF)是一种新型替诺福韦前药,已在美欧获批用于治疗青少年和成人慢性乙型肝炎。TAF在较低剂量下更高效地将活性代谢物递送至靶细胞,减少全身暴露。在慢性乙型肝炎患者中,TAF疗效与替诺福韦二吡呋酯(TDF)相当,但骨和肾毒性更低。两项大型随机3期研究48周结果显示,TAF可能是TDF的良好替代选择。

要点

  • TAF在慢性乙型肝炎患者中疗效与TDF相当,但骨和肾毒性更低。
  • TAF在肾功能损害患者中无需调整剂量,且因安全性更好可减少监测强度。
  • TAF短期(48周)骨肾获益能否转化为长期获益尚待明确。

核心结论

  • TAF可能是治疗慢性乙型肝炎时TDF的良好替代选择。

研究设计与样本

  • 两项大型随机3期研究,治疗48周后的结果。

主要发现

  • 在慢性乙型肝炎患者中,TAF似乎与TDF一样有效,且骨和肾毒性更低。
  • TAF在肾功能损害患者中无需调整剂量,且因安全性更好可减少监测强度。

关键数值与推荐

  • TAF已在美欧获批用于治疗青少年和成人慢性乙型肝炎。

临床怎么用

  • TAF可用于慢性乙型肝炎治疗,尤其适用于需关注骨肾毒性或肾功能损害的患者。

局限性

  • 48周试验中观察到的短期骨肾获益能否转化为长期治疗中的骨和肾健康改善尚待明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tenofovir alafenamide fumarate (TAF), a new prodrug of tenofovir and a potential successor of tenofovir disoproxil fumarate (TDF), has been approved in the United States and Europe for treating adolescents and adults with chronic hepatitis B infection. TAF is formulated to deliver the active metabolite to target cells more efficiently than TDF at lower doses, thereby reducing systemic exposure to tenofovir. In patients with chronic hepatitis B, TAF appears to be as effective as TDF, with lower bone and renal toxicity. TAF has the potential advantages that dose adjustment is not required in patients with renal impairment, and monitoring can be less intense because of the better safety profile. Results from 2 large, randomized, phase 3 studies after 48 weeks of therapy have shown that TAF may be a good alternative to TDF for treating chronic hepatitis B. Whether the short-term benefits observed in these 48-week trials will translate into improvements in bone and renal health in patients receiving long-term treatment remains to be seen.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Buti M, Riveiro-Barciela M, Esteban R, et al. Tenofovir Alafenamide Fumarate: A New Tenofovir Prodrug for the Treatment of Chronic Hepatitis B Infection. J Infect Dis. 2017. PMID: 29156043. doi:10.1093/infdis/jix135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。